Merck
This article was originally published in The Tan Sheet
Executive Summary
Douglas Greene, MD, named to the newly created position of Exec VP-Clinical Sciences & Product Development, overseeing the research lab division's drug development process, including clinical, regulatory, biostatistics and project planning and management functions. Greene served on FDA's Endocrinologic & Metabolic Diseases Advisory Committee between 1994 and 1998, where he helped analyze the NDA for Merck's Zocor cholesterol-lowering agent. Senior VP-Clinical & Regulatory Affairs Eve Slater, MD, who oversees Merck Rx-to-OTC switches, will report to Greene. Merck is examining the switch potential of its cholesterol-lowering drug Mevacor (1see story, p. 3)